The purinergic receptor P2X7 as a modulator of viral vector-mediated antigen cross-presentation

Front Immunol. 2024 Apr 22:15:1360140. doi: 10.3389/fimmu.2024.1360140. eCollection 2024.

Abstract

Introduction: Modified Vaccinia Virus Ankara (MVA) is a safe vaccine vector inducing long- lasting and potent immune responses. MVA-mediated CD8+T cell responses are optimally induced, if both, direct- and cross-presentation of viral or recombinant antigens by dendritic cells are contributing.

Methods: To improve the adaptive immune responses, we investigated the role of the purinergic receptor P2X7 (P2RX7) in MVA-infected feeder cells as a modulator of cross-presentation by non-infected dendritic cells. The infected feeder cells serve as source of antigen and provide signals that help to attract dendritic cells for antigen take up and to license these cells for cross-presentation.

Results: We demonstrate that presence of an active P2RX7 in major histocompatibility complex (MHC) class I (MHCI) mismatched feeder cells significantly enhanced MVA-mediated antigen cross-presentation. This was partly regulated by P2RX7-specific processes, such as the increased availability of extracellular particles as well as the altered cellular energy metabolism by mitochondria in the feeder cells. Furthermore, functional P2RX7 in feeder cells resulted in a delayed but also prolonged antigen expression after infection.

Discussion: We conclude that a combination of the above mentioned P2RX7-depending processes leads to significantly increased T cell activation via cross- presentation of MVA-derived antigens. To this day, P2RX7 has been mostly investigated in regards to neuroinflammatory diseases and cancer progression. However, we report for the first time the crucial role of P2RX7 for antigen- specific T cell immunity in a viral infection model.

Keywords: Modified Vaccinia Virus Ankara; P2RX7; cross-presentation; cytokines; extracellular vesicles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigen Presentation / immunology
  • Antigens, Viral / immunology
  • CD8-Positive T-Lymphocytes* / immunology
  • Cross-Priming* / immunology
  • Dendritic Cells* / immunology
  • Dendritic Cells* / metabolism
  • Genetic Vectors
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Receptors, Purinergic P2X7* / immunology
  • Receptors, Purinergic P2X7* / metabolism
  • Vaccinia virus* / immunology
  • Viral Vaccines / immunology

Substances

  • Receptors, Purinergic P2X7
  • Antigens, Viral
  • P2rx7 protein, mouse
  • Viral Vaccines

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Grants GK1949/2 and DR632/2-1 project No 452147069 to ID and by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 812915 to ID. EA and FDV were supported by grants from the Italian association for cancer research (AIRC grant numbers: IG 22837, IG 13025 and IG 18581).